PMID- 22641321
OWN - NLM
STAT- MEDLINE
DCOM- 20120921
LR  - 20141120
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 16
IP  - 3
DP  - 2012 Jun 1
TI  - Managing side effects of the novel taxane cabazitaxel in castrate-resistant 
      prostate cancer.
PG  - 286-91
LID - 10.1188/12.CJON.286-291 [doi]
AB  - Cabazitaxel, a novel taxane, was approved in June 2010 by the U.S. Food and Drug 
      Administration for treatment of metastatic castrate-resistant prostate cancer 
      (mCRPC) in men previously treated with docetaxel. In TROPIC (N = 755), an 
      open-label, randomized, phase III trial, cabazitaxel (plus prednisone) was 
      associated with improvement in median overall survival compared with mitoxantrone 
      plus prednisone (15.1 versus 12.7 months, p < 0.0001) in patients with mCRPC who 
      had progressed following docetaxel-based regimens. That corresponds to a 30% 
      relative reduction in risk of death compared with the mitoxantrone regimen. In 
      addition, significant benefit existed in median progression-free survival with 
      cabazitaxel versus the mitoxantrone regimen (2.8 versus 1.4 months, p < 0.0001). 
      Most common adverse events (AEs) associated with cabazitaxel were hematologic; 
      the rates (all grade) of neutropenia, leukopenia, and anemia were greater than 
      90%. Diarrhea, fatigue, asthenia, and back pain were the most common grade 3 or 
      higher nonhematologic AEs. Because expected AEs from cabazitaxel therapy can 
      delay or even interrupt treatment, oncology nurses need to be aware of those 
      risks and their management. This article reviews the vital role of nurses in 
      identifying patients at high risk for AEs associated with cabazitaxel therapy and 
      reviews strategies for prevention and management of symptoms.
FAU - Doyle-Lindrud, Susan
AU  - Doyle-Lindrud S
AD  - School of Nursing, Columbia University, New York, NY, USA. smd9@columbia.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Taxoids)
RN  - 51F690397J (cabazitaxel)
MH  - Antineoplastic Agents/*adverse effects
MH  - Clinical Trials, Phase III as Topic
MH  - Fatigue/*chemically induced/nursing
MH  - Gastrointestinal Diseases/*chemically induced/nursing
MH  - Humans
MH  - Infusions, Intravenous/adverse effects
MH  - Male
MH  - Neutropenia/*chemically induced/nursing
MH  - Nursing Assessment
MH  - Oncology Nursing
MH  - Orchiectomy
MH  - Prostatic Neoplasms/*drug therapy/nursing
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Taxoids/*adverse effects
EDAT- 2012/05/30 06:00
MHDA- 2012/09/22 06:00
CRDT- 2012/05/30 06:00
PHST- 2012/05/30 06:00 [entrez]
PHST- 2012/05/30 06:00 [pubmed]
PHST- 2012/09/22 06:00 [medline]
AID - 823P473367111380 [pii]
AID - 10.1188/12.CJON.286-291 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2012 Jun 1;16(3):286-91. doi: 10.1188/12.CJON.286-291.